Hypofractionated radiotherapy has shown less impact on peripheral blood lymphocytes in patients with locally advanced pancreatic cancer.17 It can also curb myeloid-derived suppressor cell recruitment to tumours, decrease PD-L1 expression on tumour surfaces and yield improved tumour growth inhibition rates compared with conventional fractionation in mice,18 even displaying abscopal effects when paired with immunotherapy.19 These above findings provide a theoretical basis for the clinical trials of SCRT combined with PD-1/PD-L1 antibody and suggest the prospect of their application. The gene discussed is CD274; the disease is pancreatic neoplasm.